Generics portfolio


Brand portfolio

Our brand division, Almatica Pharma, Inc. is focused on the acquisition of mature brand Rx products.

Established in 2008, Almatica Pharma has a current portfolio that includes pain, urology, and nonsteroidal anti-inflammatory (NSAIDs).

Almatica’s portfolio includes:

  • Naprelan (naproxen sodium) controlled-release tablets. See naprelanus.com for prescribing information with Boxed Warning
  • Macrodantin (nitrofurantoin macrocrystals) capsules.
  • Macrobid (nitrofurantoin monohydrate / macrocrystals) capsules.

Almatica is led by an experienced brand pharmaceutical management team and our current operations consist of established systems to support all aspects of brand product management including regulatory affairs, sales, marketing, customer service, and pharmacovigilance.

Fast growing product portfolio

The group’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. North America is Alvogen’s largest market with approximately half of the group’s sales. Other key markets include Hungary, Romania, South Korea, Bulgaria, Serbia, Russia, Ukraine, China, Thailand and Taiwan. Contact regional offices for information on product offering in your country. In the U.S., Alvogen focuses on difficult-to-make formulations and high-barrier products.

  • 200 Pharmaceutical projects
    in development
  • 50+ U.S. Pipeline
  • 2,300Global employees

Quality compliance

At our Norwich, New York manufacturing headquarters, Alvogen successfully meets – and often exceeds – quality and compliance requirements.

Read More

Customer Center

Looking for purchase orders, account information and contact to customer service? Log into your customer account and get an overview of all your previous transactions.

Read more

Connect with Alvogen Americas

Would you like to learn more about our portfolio, business development, or do you have an idea for partnership or future collaboration? We would like to hear from you.